Opin vísindi

Fletta eftir höfundi "Inderberg, Else Marit"

Fletta eftir höfundi "Inderberg, Else Marit"

Röðun: Raða: Niðurstöður:

  • Icon
    ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma 
    Mensali, Nadia; Köksal, Hakan; Joaquina, Sandy; Wernhoff, Patrik; Casey, Nicholas P.; Romecin, Paola; Panisello, Carla; Rodriguez, René; Vimeux, Lene; Juzeniene, Asta; Myhre, Marit R.; Fåne, Anne; Ramírez, Carolina Castilla; Maggadottir, Solrun Melkorka; Duru, Adil Doganay; Georgoudaki, Anna Maria; Grad, Iwona; Maturana, Andrés Daniel; Gaudernack, Gustav; Kvalheim, Gunnar; Carcaboso, Angel M.; de Alava, Enrique; Donnadieu, Emmanuel; Bruland, Øyvind S.; Menendez, Pablo; Inderberg, Else Marit; Wälchli, Sébastien (2023-06-08)
    Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable ...
  • Icon
    A phase I/II escalation trial design T-RAD : Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT) 
    Maggadóttir, Sólrún Melkorka; Kvalheim, Gunnar; Wernhoff, Patrik; Sæbøe-Larssen, Stein; Revheim, Mona Elisabeth; Josefsen, Dag; Wälchli, Sébastien; Helland, Åslaug; Inderberg, Else Marit (2022-11-10)
    Background: Adoptive cellular therapy (ACT) with genetically modified T cells aims to redirect T cells against resistant cancers through introduction of a T cell receptor (TCR). The Radium-4 TCR was isolated from a responding patient in a cancer ...
  • Icon
    Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy 
    Dillard, Pierre; Köksal, Hakan; Maggadóttir, Sólrún Melkorka; Winge-Main, Anna; Pollmann, Sylvie; Menard, Mathilde; Myhre, Marit Renée; Mælandsmo, Gunhild M.; Flørenes, Vivi Ann; Gaudernack, Gustav; Kvalheim, Gunnar; Wälchli, Sébastien; Inderberg, Else Marit (2021-03-03)
    T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel ...